Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Metabolic gene polymorphism frequencies in control populations.
- S. Garte, L. Gaspari, +63 authors E. Taioli
- Biology, Medicine
- Cancer epidemiology, biomarkers & prevention : a…
- 1 December 2001
Using the International Project on Genetic Susceptibility to Environmental Carcinogens (GSEC) database containing information on over 15,000 control (noncancer) subjects, the allele and genotype… Expand
Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism
- P. Bohanec Grabar, D. Logar, B. Lestan, V. Dolžan
- Biology, Medicine
- European Journal of Clinical Pharmacology
- 8 July 2008
ObjectiveMethotrexate (MTX) is a disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis (RA). Genetic polymorphisms of reduced folate carrier (RFC1 A80G), P-glycoprotein… Expand
Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk.
- S. Benhamou, Won Jin Lee, +30 authors E. Taioli
- Medicine
- Carcinogenesis
- 1 August 2002
Susceptibility to lung cancer may in part be attributable to inter-individual variability in metabolic activation or detoxification of tobacco carcinogens. The glutathione S-transferase M1 (GSTM1)… Expand
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium
- C. H. van der Wouden, A. Cambon-Thomsen, +23 authors H. Guchelaar
- Medicine, Engineering
- Clinical pharmacology and therapeutics
- 1 March 2017
Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been… Expand
CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls
CYP1A1 is involved in the metabolism of benzopyrene, a suspected lung carcinogen; it is therefore conceivable that genetically determined variations in its activity modify individual susceptibility… Expand
Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose
- D. Heřman, I. Locatelli, +5 authors V. Dolžan
- Biology, Medicine
- The Pharmacogenomics Journal
- 2005
Warfarin is an anticoagulant drug with narrow therapeutic index and high interindividual variability in dose requirement. S-warfarin is metabolized mainly by polymorphic cytochrome P450 (CYP) 2C9. We… Expand
Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia.
- V. Dolžan, J. Sólyom, +12 authors T. Battelino
- Biology, Medicine
- European journal of endocrinology
- 1 July 2005
OBJECTIVE
To analyze the mutational spectrum of steroid 21-hydroxylase (CYP21) and the genotype- phenotype correlation in patients with congenital adrenal hyperplasia (CAH) registered in the Middle… Expand
The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.
- D. Herman, P. Peternel, M. Stegnar, K. Breskvar, V. Dolžan
- Biology, Medicine
- Thrombosis and haemostasis
- 12 April 2006
The degree of interpatient variability in the warfarin dose required to achieve the desired anticoagulant response can only partly be explained by polymorphisms in the CYP2C9 gene, suggesting that… Expand
Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review.
- S. Raimondi, V. Paracchini, +39 authors E. Taioli
- Medicine
- American journal of epidemiology
- 1 December 2006
Lung cancer is the most common malignancy in the Western world, and the main risk factor is tobacco smoking. Polymorphisms in metabolic genes may modulate the risk associated with environmental… Expand
The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose
- D. Herman, I. Locatelli, +6 authors V. Dolžan
- Medicine
- European Journal of Clinical Pharmacology
- 22 March 2006
AimsWarfarin is a frequently used anticoagulant drug with narrow therapeutic index and high interindividual variability in the dose requirement. We have previously shown that warfarin dose is… Expand